Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC  

作　　者：Feifei Li Youyang Shi Mei Ma Xiaojuan Yang Xiaosong Chen Ying Xie Sheng Liu 

机构地区：[1]Department of Breast Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,China [2]Institute of Chinese Traditional Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,China [3]Institute of Toxicology,School of Public Health,Lanzhou University,Lanzhou,730000,China [4]Department of General Surgery,Comprehensive Breast Health Center,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200001,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第10期1450-1467,共18页药物分析学报（英文版）

基　　金：This work was supported by the National Natural Science Foundation of China(Grant No.:81774308);the Multi-center Clinical Research Project for Major Diseases of Shanghai Shenkang Hospital Development Center,China(Grant No.:SHDC2020CR1050B);the High-level University Building Innovation Team,China(Grant No.:601521D).

摘　　要：Trastuzumab has improved survival rates in human epidermal growth factor receptor 2(HER2)-positive breast cancer(BC),but drug resistance leads to treatment failure.Natural killer(NK)cell-mediated antibody-dependent cell cytotoxicity(ADCC)represents an essential antitumor immune mechanism of trastuzumab.Traditional Chinese medicine(TCM)has been used for centuries to treat diseases because of its capacity to improve immune responses.Xianling Lianxia formula(XLLXF),based on the principle of“strengthening body and eliminating toxin”,exhibits a synergistic effect in the trastuzumab treatment of patients with HER2-positive BC.Notably,this synergistic effect of XLLXF was executed by enhancing NK cells and ADCC,as demonstrated through in vitro co-culture of NK cells and BC cells and in vivo intervention experiments.Mechanistically,the augmented impact of XLLXF on NK cells is linked to a decrease in cytokine inducible Src homology 2(SH2)containing protein(CISH)expression,which in turn activates the Janus kinase 1(JAK1)/signal transducer and activator of transcription 5(STAT5)pathway.Collectively,these findings suggested that XLLXF holds promise for enhancing NK cell function and sensitizing patients with HER2-positive BC to trastuzumab.

关 键 词：HER2-positive breast cancer Traditional chinese medicine TRASTUZUMAB NK cell ADCC effect 

分 类 号：R96[医药卫生—药理学]